![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sunovion Pharmaceuticals Canada Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
Sunovion Pharmaceuticals Canada Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
August 23, 2011
Sunovion Pharmaceuticals Canada announced a new drug submission for Lurasidone HCl, to treat adult patients with schizophrenia, has been accepted for review by Health Canada.
Digital Journal
Digital Journal
Upcoming Events
-
21Oct